Biocryst Pharmaceuticals, Inc.

Biocryst Pharmaceuticals, Inc. company information, Employees & Contact Information

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. We are a commercial-stage biotech company with US headquarters in Durham, North Carolina. Our European headquarters is in Dublin, Ireland, and our Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices around the world. As world leaders in structure-guided drug design, we draw on the strengths and expertise of all our colleagues—from those of us in the field or behind the scenes in our labs, to others based in home offices and around the globe. To view our LinkedIn community guidelines, please visit https://www.biocryst.com/social-community-guidelines/

Company Details

Employees
640
Founded
-
Address
4505 Emperor Blvd., Suite 200,united States
Phone
9198591314
Email
in****@****yst.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Durham, NC
Looking for a particular Biocryst Pharmaceuticals, Inc. employee's phone or email?

Biocryst Pharmaceuticals, Inc. Questions

News

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting - Yahoo Finance

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting Yahoo Finance

BioCryst Pharmaceuticals to Present Key Research on ORLADEYO® at ACAAI Annual Scientific Meeting 2025 - Quiver Quantitative

BioCryst Pharmaceuticals to Present Key Research on ORLADEYO® at ACAAI Annual Scientific Meeting 2025 Quiver Quantitative

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile - Business Wire

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile Business Wire

BioCryst (Nasdaq: BCRX) to present APeX-P interim pediatric HAE data on ORLADEYO - Stock Titan

BioCryst (Nasdaq: BCRX) to present APeX-P interim pediatric HAE data on ORLADEYO Stock Titan

BioCryst to Report Third Quarter 2025 Financial Results on November 3 - GlobeNewswire

BioCryst to Report Third Quarter 2025 Financial Results on November 3 GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance

115,000 Options & 91,450 RSUs — BioCryst Grants Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Stock Titan

115,000 Options & 91,450 RSUs — BioCryst Grants Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Stock Titan

BioCryst Pharmaceuticals Completes $250 Million Sale of European ORLADEYO Business to Neopharmed Gentili - Quiver Quantitative

BioCryst Pharmaceuticals Completes $250 Million Sale of European ORLADEYO Business to Neopharmed Gentili Quiver Quantitative

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

$250M Deal: BioCryst Divests European ORLADEYO Business at 5.4x Sales Multiple, Retains US Focus - Stock Titan

$250M Deal: BioCryst Divests European ORLADEYO Business at 5.4x Sales Multiple, Retains US Focus Stock Titan

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business - GlobeNewswire

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business GlobeNewswire

BioCryst Announces Departure of Dr. Helen Thackray - GlobeNewswire

BioCryst Announces Departure of Dr. Helen Thackray GlobeNewswire

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development - Yahoo Finance

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development Yahoo Finance

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI - Yahoo Finance

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI Yahoo Finance

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse - GlobeNewswire

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse GlobeNewswire

Biotech Developer BioCryst Pharmaceuticals to Present Latest Updates at Major Cantor Healthcare Conference - Stock Titan

Biotech Developer BioCryst Pharmaceuticals to Present Latest Updates at Major Cantor Healthcare Conference Stock Titan

71,400 RSUs and 36,700 Stock Options: BioCryst's Latest Employee Compensation Package Details - Stock Titan

71,400 RSUs and 36,700 Stock Options: BioCryst's Latest Employee Compensation Package Details Stock Titan

BioCryst Pharmaceuticals to Announce Q2 2025 Financial Results and Host Conference Call on August 4, 2025 - Quiver Quantitative

BioCryst Pharmaceuticals to Announce Q2 2025 Financial Results and Host Conference Call on August 4, 2025 Quiver Quantitative

BioCryst Awards Massive Stock Package: 10 New Hires Get 126,450 Shares in Options and RSUs - Stock Titan

BioCryst Awards Massive Stock Package: 10 New Hires Get 126,450 Shares in Options and RSUs Stock Titan

BioCryst Appoints Steve Frank to Board of Directors - Yahoo Finance

BioCryst Appoints Steve Frank to Board of Directors Yahoo Finance

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years - Yahoo Finance

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years Yahoo Finance

BioCryst's R&D Chief Departs Following CEO Race: What This Means for ORLADEYO and 2 Pipeline Drugs - Stock Titan

BioCryst's R&D Chief Departs Following CEO Race: What This Means for ORLADEYO and 2 Pipeline Drugs Stock Titan

BioCryst Pharmaceuticals Appoints Babar Ghias as Chief Financial Officer and Head of Corporate Development - Quiver Quantitative

BioCryst Pharmaceuticals Appoints Babar Ghias as Chief Financial Officer and Head of Corporate Development Quiver Quantitative

BioCryst Unveils Groundbreaking Research on HAE Treatment Burden in Young Patients Under 12 - Stock Titan

BioCryst Unveils Groundbreaking Research on HAE Treatment Burden in Young Patients Under 12 Stock Titan

BioCryst Announces Sale of European ORLADEYO® - GlobeNewswire

BioCryst Announces Sale of European ORLADEYO® GlobeNewswire

BioCryst Pharmaceuticals' ORLADEYO® Approved for National Reimbursement in the Netherlands for HAE Prevention - Quiver Quantitative

BioCryst Pharmaceuticals' ORLADEYO® Approved for National Reimbursement in the Netherlands for HAE Prevention Quiver Quantitative

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update GlobeNewswire

ORLADEYO Clinical Trial Results: 86% Attack Reduction Transforms Life for HAE Patients of All Ages - Stock Titan

ORLADEYO Clinical Trial Results: 86% Attack Reduction Transforms Life for HAE Patients of All Ages Stock Titan

BioCryst Taps Dealmaking Powerhouse as New CFO: $80B Transaction Expert to Drive Growth Strategy - Stock Titan

BioCryst Taps Dealmaking Powerhouse as New CFO: $80B Transaction Expert to Drive Growth Strategy Stock Titan

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones - Yahoo Finance

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones Yahoo Finance

BioCryst Expands Team with 57,000 Share RSU Package: Latest Details on New Hiring Spree - Stock Titan

BioCryst Expands Team with 57,000 Share RSU Package: Latest Details on New Hiring Spree Stock Titan

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) - Yahoo Finance

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) Yahoo Finance

FDA Fast-Tracks First-Ever Oral HAE Treatment for Children Under 12: September Decision Expected - Stock Titan

FDA Fast-Tracks First-Ever Oral HAE Treatment for Children Under 12: September Decision Expected Stock Titan

BioCryst Pharmaceuticals Provides 2025 Revenue Guidance and Pipeline Updates for ORLADEYO and New Drug Applications - Nasdaq

BioCryst Pharmaceuticals Provides 2025 Revenue Guidance and Pipeline Updates for ORLADEYO and New Drug Applications Nasdaq

BioCryst Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 - Quiver Quantitative

BioCryst Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 Quiver Quantitative

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24 - The Manila Times

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24 The Manila Times

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) - The Manila Times

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) The Manila Times

BioCryst to Report Second Quarter 2024 Financial Results on August 5 - Stock Titan

BioCryst to Report Second Quarter 2024 Financial Results on August 5 Stock Titan

BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013 - Yahoo Finance

BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013 Yahoo Finance

BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update - Yahoo Finance

BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update Yahoo Finance

BioCryst Reports Initial Clinical Data with Oral Factor D - GlobeNewswire

BioCryst Reports Initial Clinical Data with Oral Factor D GlobeNewswire

BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets - GlobeNewswire

BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets GlobeNewswire

BioCryst Appoints Vincent Milano to Board of Directors - citybiz

BioCryst Appoints Vincent Milano to Board of Directors citybiz

BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema - Yahoo Finance

BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema Yahoo Finance

Top Biocryst Pharmaceuticals, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant